Ruti Aga: Forged Prescription Turns 6-Year Ban into Career End; Media Reports Calling Glucocorticoid a Steroid Are Misleading

At first glance, this is another anti-doping case. One athlete, one positive sample, one ban. But when I read the Athletics Integrity Unit (AIU) statement frame by frame, the real story was where no number existed. Ruti Aga's case is not about performance; it is about a document that never existed. The 2026 Tokyo Marathon. Ruti Aga won in 2:20:40. It was a World Marathon Major title, the biggest achievement of her career. After that, she finished second at three Majors. But this year, in March, after winning a half marathon in China, AIU's doping control reached her. The sample contained methylprednisolone. It is a glucocorticoid, classified under S9 on the WADA Prohibited List. Many media reports called it a 'prohibited steroid' and a 'performance-enhancing drug' — that is technically incorrect. It is not an anabolic steroid (S1). Here the real question arises. S9 glucocorticoids are prohibited only in-competition, and only by injection, oral, or rectal routes. A therapeutic knee injection is entirely legal out-of-competition. In Aga's case, this was the path of defense — timing, route, and medical necessity. But she chose the path that could never work. She forged a prescription. The AIU investigation found that the prescription came from a clinic that did not exist. The 'doctor' who issued it was a family member with no medical registration. That family member claimed to have used 'an old prescription pad from a former workplace.' The clinic itself disowned the document. Three independent verification failures. Now the arithmetic. The AIU imposed a two-year sanction — for the presence violation. Then four years — for tampering. Total six years. This is standard WADA Code arithmetic. But here is a crucial point — the panel rejected the 'no-significant-fault' mitigation that could have reduced the presence sanction. This means the panel found Aga acted not intentionally, but negligently. Had Aga possessed genuine medical records and been able to explain route/timing, the presence charge could have been argued at the no-fault level — potentially a reprimand or a substantially reduced period. And there would have been no tampering charge at all. In the best-case scenario, a TUE-consistent treatment plan and correct washout timing meant no case whatsoever. By forging the document, she destroyed her only viable defense. This case is not just one athlete's mistake. It is a failure of medical governance in East African road running. A properly managed athlete would either hold a TUE or observe the WADA route-specific washout period. Neither happened. The 'doctor' being a family member is the signature of an athlete operating without a credentialed team physician. The knee injury was not an acute event; it was likely chronic. The attempt to manufacture a paper trail suggests a repeated pattern of informal treatment, not a single lapse. The irony here is that methylprednisolone has no proven endurance benefit. It is an anti-inflammatory drug. Intra-articular injection for knee synovitis is standard sports-medicine practice in distance runners. Medically, it makes sense. But legally, it is fatal — because the forgery is the decisive fact. A genuine document would have been defended with real records. Aga is 32. The six-year ban starts on September 10, the date of provisional suspension. That means she will return at approximately age 38. Given Ethiopia's women's marathon depth, a 38-year-old returnee with a doping record is essentially unselectable. This ban is functionally a lifetime ban on her career. But there is another aspect that escapes media attention. Aga's 2026 Tokyo title and three Major second places — these results are not automatically annulled. The AIU statement does not state the disqualification scope. Standard practice is that the result and prize money from the competition where the sample was collected are voided. But results before that date — including the 2026 Major win — are not automatically annulled. So her historical standing is bifurcated: the record of a genuinely elite marathoner stands, but commercially she is now radioactive. Now consider China's half-marathon circuit. It functions as a lucrative, low-risk income tier for East African marathoners between Majors. Large appearance-fee budgets, deep elite fields, and AIU testing. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. Aga's case is another example of this collision. Final question: Is this disproportionate enforcement? A six-year ban for a glucocorticoid — a substance with no proven performance benefit — is a striking outcome. It will be cited both as evidence of AIU rigor and as evidence of disproportionate enforcement against African road runners. But the data tells a different story. Aga's case is not an outlier; it belongs to a recognizable family of East African road-racing cases where the initial substance violation is compounded by a fabricated or altered explanation. The enforcement frontier has shifted from 'detection' to 'document verification.' If I pick one signal, it is this: multiple similarly-profiled cases are likely in the pipeline, because the same informal medical networks serve many athletes in the same training clusters. The question is not whether the next case will come. The question is whether the Ethiopian federation and management agents will hear this warning, or wait for the next forged prescription pad to be used.